# Incidence of ploidy abnormalities according to PGT-A indication in embryos derived from normally fertilised oocytes

Lorena Rodrigo, Adedoyin Akinwole, Paula Regina Queiroz, Inmaculada Campos-Galindo, Cristina Patassini, Refik Kayali, Bruno Coprerski, Laura Girardi, Nasser Al Asmar, Carmen Rubio


lorena.rodrigo@igenomix.com Igenomix Spain, Vitrolife Group

All authors are employees of Igenomix, a company providing reproductive genetic services, part of Vitrolife Group



## Ploidy assessment in PGT-A

**PGT-A NGS-based platforms** compare chromosome copy number (CN) ratios to identify aneuploides (chromosome gain/losses), but **cannot distinguish variations in the number of complete chromosome sets** (ploidy)





Haploidy and triploidy are both compatible with preimplantation embryonic development.

Triploidy can be found in 10% of chromosomally abnormal spontaneous miscarriages and is usually not compatible with development to term (Boué et al., 1975; Hassold et al., 1980; Plachot et al., 1989, Strom et al., 1990).



## **Ploidy assessment in PGT-A**


Incorporating SNP analysis to the NGS-based PGT-A workflow allows the integration of genotype information and copy-number analysis to incorporate ploidy assessment within a standard PGT-A workflow














# Incidence of haploidy and triploidy in abnormally fertilized oocytes

Journal of Assisted Reproduction and Genetics https://doi.org/10.1007/s10815-024-03278-4

GENETICS

Incidence of haploidy and triploidy in trophectoderm biopsies of blastocysts derived from normally and abnormally fertilized oocytes

Laura Girardi <sup>1</sup> O · Cristina Patassini <sup>1</sup> · Jose Miravet Valenciano <sup>2</sup> O · Yoshimi Sato <sup>3</sup> · Natalia Fagundes Cagnin <sup>4</sup> · Jose Antonio Castellón <sup>5</sup> · Francesco Cogo <sup>1</sup> · Paola Zambon <sup>1</sup> · David Blesa <sup>2</sup> O · Jorge Jimenez Almazan <sup>2</sup> · Adedoyin Akinwole <sup>6</sup> · Bruno Coprerski <sup>4</sup> · Carmen Rubio <sup>2</sup> O



Conventional static PN evaluation




Fig. 4 Global distribution of ploidy configurations in abnormally fertilized zygotes with different pronuclear statuses. Overview of ploidy results distribution (diploid, haploid, and triploid) reported for each

group of embryos concerning the number of pronuclei (PN) detected. Ploidy results in a 0PN-derived embryos, b 1PN-derived embryos, c 2.1PN-derived embryos, and d 3PN-derived embryos

PN evaluation by time-lapse monitoring system





Fig. 5 Ploidy constitution of abnormally fertilized zygotes confirmed by time-lapse observation. Overview of ploidy result distribution (diploid, haploid, and triploid) reported for a 0PN, b 1PN, c 2.1PN,

and d 3PN-derived embryos when identifying pronuclear (PN) status with time-lapse instruments

Although time-lapse monitoring systems improve the assessment of ploidy status in embryos with atypical PN patterns, SNP analysis identifies some of them as diploid and therefore, potentially transferable



## Incidence of haploidy and triploidy in normally fertilized oocytes



2024




Fig. 2 Global distribution of ploidy results in normally fertilized zygotes. Ploidy status distribution in 1982 2PN-derived blastocysts or presumed normally fertilized embryos

SNP analysis identifies 1% of 2PN embryos with abnormal ploidy (triploid and haploid), allowing them to be deselected for transfer and potentially increasing reproductive outcomes



Journal of Assisted Reproduction and Genetics

https://doi.org/10.1007/s10815-024-03278-4

# **Objectives**

✓ To evaluate the incidence of abnormal ploidy in embryos derived from normally fertilised oocytes (2PN).

✓ To evaluate the impact of different PGT-A indications on ploidy results.

✓ To evaluate the impact of female age on ploidy results.




## **Material and methods**

Retrospective study (November 2023 – November 2024) in couples performing Smart PGT-A Plus (analysed at Igenomix USA, Canada, Brazil and Spain)

Ploidy, contamination and cohort testing in embryos derived from normally fertilised oocytes (2PN)


## **Samples**





## **Material and methods**


#### **Smart PGT-A Plus**



Ion Reproseq PGS kit and a proprietary bioinformatics pipeline (v2.0) were used for 24-chromosome aneuploidy testing.

Custom Ion AmpliSeq panel of **357 selected SNPs** 

(Thermo Fisher Scientific, USA)



Proprietary algorithm for data analysis (v1.0)







Ploidy detection (triploidy, haploidy)




DNA contamination (external cell/DNA and maternal cell contamination)

Cohort check
(genetic relatedness between embryos in a cohort)



# Incidence of abnormal ploidy in embryos derived from normally fertilised oocytes (2PN)



2,841 embryos informative for Ploidy and Contamination


**1,825** embryos considered for Cohort testing (cohort with 2 or more analysable embryos)

- Informative for cohort testing: 99.5%
- All the informative embryos showed genetic relatedness to their cohort




## Incidence of abnormal ploidy in embryos derived from normally fertilised oocytes (2PN)

## 1.4% (41/2827) TRIPLOID / HAPLOID EMBRYOS





## Incidence of abnormal ploidy according to PGT-A indication



a-a p<0.01; b-bp<0.05; c-c p<0.001; Fisher's exact test vs GP

#### **Embryos with abnormal ploidy:**

- Significantly increased incidence in AMA vs GP
- Higher trend in RPL and MF vs GP
- Similar incidence in RIF vs GP

#### **Triploid embryos:**


- Significantly increased incidence in AMA vs GP
- Higher trend in RPL vs GP
- Similar incidence in MF, RIF and GP

#### **Haploid embryos:**

- Higher trend in RPL and MF vs GP
- Similar incidence in AMA, RIF and GP




# Incidence of abnormal ploidy according to female age



An increase in the number of embryos with abnormal ploidy is observed with the female age, which becomes more pronounced in women >40 years of age



# Incidence of abnormal ploidy in two age groups



a-c p<0.05; b-d p<0.01; a-e, b-f p<0.001; Fisher's exact test

#### **Triploid embryos:**

- Significantly higher incidence in AMA >40 vs. AMA ≤40 and GP
- Similar incidence in AMA ≤40 years and GP

#### **Haploid embryos:**

Similar incidence in AMA >40, AMA ≤40 and GP



### **Conclusions**

- 1.4% of blastocyts derived from normal fertilization (2PN) were identified as triploid or haploid.
- 2. Patients with AMA (>35 years) had the highest incidence of embryos with abnormal ploidy (2.6%), mainly related to triploidy, and this was more prevalent in woman >40 yrs (4.5%).
- 3. Young patients (≤35) with clinical history of RPL (2.3%) and MF (1.4%) showed particularly high rates of triploid or haploid embryos compared to good prognosis patients (0.9%).
- 4. PGT-A with ploidy and contamination analysis decreases the risk of misdiagnosis by identifying samples with non-embryonic DNA contamination and improving the diagnosis of mosaicism and embryos with intermediate sex chromosomes copy number changes.

The incorporation of SNP analysis in PGT-A results in a more accurate diagnosis with potential improvements of clinical outcomes. Our results indicate the higher impact in patients >40 yrs and in RPL patients.



# Incidence of ploidy abnormalities according to PGT-A indication in embryos derived from normally fertilised oocytes

Lorena Rodrigo, Adedoyin Akinwole, Paula Regina Queiroz, Inmaculada Campos-Galindo, Cristina Patassini, Refik Kayali, Bruno Coprerski, Laura Girardi, Nasser Al Asmar, Carmen Rubio

lorena.rodrigo@igenomix.com lgenomixSpain, Vitrolife Group

